| Diabetes Mellitus, Non-Insulin-Dependent
Jentadueto vs Kombiglyze XR
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Jentadueto vs Kombiglyze with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKombiglyze has a higher rate of injection site reactions vs Jentadueto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kombiglyze but not Jentadueto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jentadueto
Kombiglyze
At A Glance
Oral
Twice daily
DPP-4 inhibitor / biguanide
Oral
Once daily
DPP4 inhibitor + biguanide
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Individualized dosing orally twice daily with meals; starting at 2.5 mg linagliptin/500 mg metformin HCl twice daily for metformin-naive patients, maximum 2.5 mg linagliptin/1,000 mg metformin HCl twice daily; contraindicated if eGFR <30 mL/min/1.73 m2; initiation not recommended if eGFR 30-45 mL/min/1.73 m2.
Diabetes Mellitus, Non-Insulin-Dependent Administer once daily with the evening meal; individualize starting dose based on current regimen; max 5 mg saxagliptin/2,000 mg metformin HCl extended-release once daily; limit saxagliptin to 2.5 mg daily with strong CYP3A4/5 inhibitors; swallow tablets whole.
Contraindications
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to linagliptin, metformin, or any excipient in JENTADUETO
- Severe renal impairment (eGFR below 30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- History of serious hypersensitivity reaction to saxagliptin, metformin HCl, or any ingredient in KOMBIGLYZE XR, including anaphylaxis, angioedema, or exfoliative skin conditions
Adverse Reactions
Most common (>=5%) Nasopharyngitis, diarrhea (combination); diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache (metformin initiation)
Serious Lactic acidosis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, vitamin B12 deficiency, severe and disabling arthralgia, bullous pemphigoid, heart failure
Postmarketing Acute pancreatitis including fatal pancreatitis, mouth ulceration, stomatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, rash, cholestatic/hepatocellular/mixed liver injury
Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache (saxagliptin); diarrhea, nausea/vomiting (metformin)
Serious Lactic acidosis, pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid, vitamin B12 decrease
Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, bullous pemphigoid, cholestatic and hepatocellular liver injury
Pharmacology
Linagliptin is a DPP-4 inhibitor that increases active incretin hormones (GLP-1 and GIP), stimulating glucose-dependent insulin release and reducing glucagon secretion; metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Kombiglyze XR combines saxagliptin, a competitive DPP4 inhibitor that slows incretin hormone (GLP-1, GIP) inactivation to enhance glucose-dependent insulin release and suppress glucagon, and metformin HCl, a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jentadueto
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (9/12) · Qty limit (11/12)
Kombiglyze
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Jentadueto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Kombiglyze
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Jentadueto
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Kombiglyze
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Jentadueto.
No savings programs available for Kombiglyze.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JentaduetoView full Jentadueto profile
KombiglyzeView full Kombiglyze profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.